|
Press Releases |
|
|
|
Thursday, June 14, 2018 |
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research |
Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. more info >> |
|
Wednesday, June 13, 2018 |
|
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA |
Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. more info >> |
|
Monday, June 11, 2018 |
|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA |
The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. more info >> |
|
Wednesday, June 6, 2018 |
|
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting |
Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States. more info >> |
|
Tuesday, June 5, 2018 |
|
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months |
Eisai Co., Ltd. and Biogen Inc. announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (AB) levels in the brain measured by amyloid-PET (positron emission tomography). more info >> |
|
Monday, June 4, 2018 |
|
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting |
The data are included in presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. LENVIMA and KEYTRUDA are not approved for use in combination in any cancer types today. more info >> |
|
Thursday, May 31, 2018 |
|
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma |
Eisai Co., Ltd. has announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
Monday, May 28, 2018 |
|
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018 |
Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet". more info >> |
|
Friday, May 25, 2018 |
|
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease |
This novel mechanism of action elucidated is expected to lead to value enhancement and acceleration of the development of E6007 which aims to provide a new remedy for IBD patients. more info >> |
|
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib |
The FDA has indicated that the extension of the Prescription Drug User Fee Act (PDUFA) date is needed to allow additional time for review of the application. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
SGX-Listed Mooreast Appoints Norwegian Eirik Ellingsen as CEO to Drive Growth in Global Floating Offshore Wind Market
Nov 21, 2024 19:00 HKT/SGT
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 21, 2024 17:54 HKT/SGT
|
|
|
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
|
|
|
Yahoo Finance Invest Asia 2024 - Disrupting Finance: Innovations Shaping The Future
Nov 21, 2024 14:14 HKT/SGT
|
|
|
TGL Presented by SoFi Names SYNLawn As Official Synthetic Surface Partner, Providing 31,000 Square Feet of Turf for SoFi Center's Tech-Infused Field of Play
Nov 21, 2024 08:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|